TRIM63 Antibody

What is TRIM63 and why is it important in muscle research?

TRIM63, also named as IRF, MURF1, RNF28, and SMRZ, functions as an E3 ubiquitin ligase that plays a crucial role in maintaining muscle protein homeostasis. It tags sarcomere proteins with ubiquitin for subsequent degradation, making it a key regulator of muscle protein turnover . TRIM63 is primarily expressed in skeletal and cardiac muscle tissues, with particularly high expression in these tissues demonstrating its tissue-specific function . Recent studies have implicated TRIM63 variants in hypertrophic cardiomyopathy (HCM), suggesting its importance in cardiac pathophysiology . Understanding TRIM63 function is essential for research into muscle atrophy, cardiac hypertrophy, and other muscle-related diseases.

What are the common applications for TRIM63 antibodies in research?

TRIM63 antibodies are versatile tools employed across multiple experimental applications in muscle biology research:

When selecting a TRIM63 antibody, it's crucial to consider the specific application requirements. For instance, antibodies that work well for Western blotting may not perform optimally for immunohistochemistry. Always validate the antibody in your specific experimental system to obtain optimal results .

What is the molecular weight of TRIM63 protein in Western blot applications?

The calculated molecular weight of TRIM63 is approximately 40 kDa, but the observed molecular weight in experimental conditions typically ranges between 40-45 kDa . This slight discrepancy between calculated and observed weights is common for many proteins and can result from post-translational modifications, protein folding, or the presence of charged residues affecting protein migration in SDS-PAGE. When performing Western blot analysis, researchers should expect to observe TRIM63 protein bands within this 40-45 kDa range. If bands appear at significantly different molecular weights, they may represent degradation products, splice variants, or non-specific binding of the antibody.

How do I select the most appropriate TRIM63 antibody for my specific research question?

Selecting the optimal TRIM63 antibody requires careful consideration of multiple factors:

• Target epitope location: Different antibodies target distinct regions of TRIM63. For example, some antibodies target the N-terminal region, while others target specific amino acid sequences like AA 254-352 . The epitope location may affect antibody performance in specific applications, particularly if your research focuses on a particular domain of TRIM63.

• Host species and clonality: TRIM63 antibodies are available as rabbit polyclonal, mouse monoclonal, and other variations . Consider:

  • Polyclonal antibodies may provide higher sensitivity but potentially lower specificity

  • Monoclonal antibodies offer consistent production and higher specificity for a single epitope

  • The host species becomes particularly important when designing multi-color immunofluorescence experiments to avoid secondary antibody cross-reactivity

• Validated applications: Review published literature and manufacturer validation data to ensure the antibody performs well in your intended application. For example, antibody 55456-1-AP has been cited in 81 publications for Western blot and 7 publications for IHC applications .

• Species reactivity: Confirm the antibody's reactivity with your experimental model organism. While many TRIM63 antibodies react with human, mouse, and rat samples, some have broader reactivity including pig, canine, chicken, and zebrafish models .

• Experimental evidence: Request validation data from manufacturers or review published studies using the antibody in your specific application before making a selection.

What are the critical considerations when designing co-localization experiments with TRIM63?

Co-localization experiments with TRIM63 require careful experimental design to ensure reliable results:

• Antibody compatibility: When using multiple antibodies, ensure they are derived from different host species to avoid cross-reactivity. For example, when co-localizing TRIM63 with α-actinin, researchers have successfully used Flag-tagged TRIM63 detected with mouse monoclonal anti-Flag antibody in combination with Alexa Fluor 488-conjugated secondary antibodies .

• Appropriate controls: Include:

  • Single-antibody controls to assess bleed-through

  • Secondary antibody-only controls to detect non-specific binding

  • Known positive and negative controls for TRIM63 expression

• Fixation and permeabilization optimization: Different fixation methods can affect epitope accessibility. For TRIM63, successful immunofluorescence has been performed following fixation and permeabilization of cells, with subsequent incubation with primary antibodies like mouse monoclonal anti-α-actinin and appropriate secondary antibodies .

• Imaging parameters: Use sequential scanning when performing confocal microscopy to minimize spectral overlap between fluorophores.

• Quantitative analysis: For meaningful co-localization analysis, employ appropriate statistical methods and coefficients (Pearson's, Manders', etc.) rather than relying solely on visual assessment of overlap.

Published studies have successfully demonstrated co-localization between TRIM63 and ubiquitin in HeLa-His/Bio-Ub cells using a rabbit polyclonal anti-Flag antibody followed by a donkey anti-rabbit antibody conjugated with Alexa Fluor 350 and Streptavidin conjugated with Texas Red .

How should I design experiments to study TRIM63 auto-ubiquitination and substrate ubiquitination?

Studying TRIM63 ubiquitination activity requires careful experimental design:

• Cell systems: HeLa-His/Biotin-Ubiquitin cells have been successfully used to study TRIM63 auto-ubiquitination . These cells allow for the specific labeling and detection of ubiquitinated proteins.

• Expression constructs: Use of Flag-tagged wild-type and mutant TRIM63 constructs (such as TRIM63 A48V, TRIM63 I130M, and TRIM63 Q247*) enables comparative analysis of normal versus impaired ubiquitination activity .

• Detection methods:

  • Co-immunoprecipitation (Co-IP): Effective for isolating TRIM63 and its ubiquitinated substrates. After transduction with recombinant lentiviruses expressing Flag-tagged TRIM63 variants, Co-IP can be performed to assess auto-ubiquitination levels .

  • Immunofluorescence: Double staining for TRIM63 (using anti-Flag antibodies) and ubiquitin in transduced cells provides visual evidence of co-localization and auto-ubiquitination .

  • Western blotting: Quantitative analysis of ubiquitinated proteins showing characteristic laddering pattern.

• Controls: Include wild-type TRIM63 as a positive control for normal ubiquitination activity. TRIM63 Q247* has shown near complete loss of auto-ubiquitination and can serve as a negative control .

• Quantification: Perform quantitative analysis of auto-ubiquitination levels. Studies have shown 60-70% reductions in auto-ubiquitinated TRIM63 A48V and TRIM63 I130M compared to wild-type .

What are the best approaches for studying TRIM63 function in cardiac and skeletal muscle tissues?

Investigating TRIM63 function in muscle tissues can be approached through several complementary methods:

• Transgenic mouse models: Cardiac-restricted inducible tet-off transgenic mice expressing wild-type or mutant TRIM63 (A48V, I130M, Q247*) have been successfully used to study TRIM63 function in vivo . These models allow for temporal control of TRIM63 expression using doxycycline.

• Primary cell cultures:

  • Adult cardiac myocytes can be isolated and transduced with adenoviral constructs expressing TRIM63 variants .

  • These systems allow for controlled expression and detailed cellular analysis.

• Tissue analysis techniques:

  • Immunohistochemistry: TRIM63 antibodies have been validated for IHC in mouse skeletal muscle, human heart, human skeletal muscle, mouse heart, and rat brain tissues .

  • Immunofluorescence: TRIM63 antibodies have been validated for IF in mouse skeletal muscle tissue .

  • Western blot: For quantitative protein analysis from tissue lysates.

• Functional readouts:

  • Cardiac hypertrophy markers

  • MTOR-S6K and calcineurin pathway activation

  • Sarcomere protein levels

  • Muscle mass and function

• Recommended antibody dilutions for tissue analysis:

  • IHC: 1:50-1:500

  • IF-P: 1:50-1:500

  • WB: 1:1000-1:8000

How can I verify TRIM63 antibody specificity in my experimental system?

Verifying antibody specificity is crucial for obtaining reliable and reproducible results:

• Knockout/knockdown validation:

  • Use TRIM63 knockout tissues or cells as negative controls

  • Alternatively, perform siRNA or shRNA knockdown of TRIM63 to create reduced-expression controls

  • Publications using knockdown/knockout validation for TRIM63 antibodies exist and can serve as methodological guides

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide

  • A specific antibody will show reduced or abolished signal when pre-absorbed with its target peptide

  • For peptide-raised antibodies like those targeting TRIM63 AA 254-352, this is particularly relevant

• Multiple antibody validation:

  • Use multiple antibodies targeting different epitopes of TRIM63

  • Concordant results with different antibodies increase confidence in specificity

  • Available antibodies target various regions including N-terminal, AA 254-352, and AA 1-353

• Recombinant expression:

  • Express tagged versions of TRIM63 (e.g., Flag-tagged constructs)

  • Compare antibody signals with anti-tag antibody signals

  • This approach has been used successfully with Flag-tagged TRIM63 WT, p.A48V, p.I130M, and p.Q247* constructs

• Western blot molecular weight verification:

  • Confirm that the observed molecular weight matches the expected 40-45 kDa

  • Multiple bands may indicate degradation, post-translational modifications, or non-specificity

How can I optimize Western blot protocols for TRIM63 detection in muscle samples?

Optimizing Western blot protocols for TRIM63 detection requires addressing several key factors:

• Sample preparation:

  • For muscle tissue, use specialized extraction buffers containing protease inhibitors to prevent degradation

  • Consider phosphatase inhibitors if studying TRIM63 phosphorylation

  • Use approximately 30μg of protein extract for optimal detection

• Antibody selection and dilution:

  • Start with recommended dilutions (1:1000-1:8000) and optimize as needed

  • Different antibodies may perform better in different sample types

• Common issues and solutions:

• Recommended blocking conditions:

  • 5% non-fat dry milk or BSA in TBST is typically effective

  • For phospho-specific detection, BSA is preferred over milk

• Detection systems:

  • Enhanced chemiluminescence (ECL) is suitable for most TRIM63 detection

  • For low abundance samples, consider more sensitive detection systems like ECL Plus/Advanced

What are the main challenges in detecting TRIM63 in different tissue types and how can they be addressed?

TRIM63 detection varies across tissue types, with each presenting unique challenges:

• Skeletal muscle (high expression):

  • Challenge: High protein content can lead to inconsistent extraction

  • Solution: Use specialized muscle lysis buffers; mechanical homogenization followed by sonication

• Cardiac tissue (moderate to high expression):

  • Challenge: High lipid content can interfere with protein separation

  • Solution: Additional centrifugation steps; optimize detergent concentration in lysis buffer

• Non-muscle tissues (low expression):

  • Challenge: Low TRIM63 expression makes detection difficult

  • Solution: Increase protein loading; use more sensitive detection methods; longer exposure times; consider immunoprecipitation before Western blotting

• Cross-reactivity considerations:

  • Challenge: TRIM family proteins share homology

  • Solution: Verify antibody specificity against other TRIM proteins; use tissues from TRIM63 knockout animals as negative controls

• Application-specific optimizations:

How do I address contradictory results when studying TRIM63 in different experimental models?

When facing contradictory results across experimental models, consider these systematic troubleshooting approaches:

• Species-specific differences:

  • TRIM63 function may vary between species

  • Verify antibody cross-reactivity with your specific species (human, mouse, rat, etc.)

  • TRIM63 antibodies have demonstrated reactivity with multiple species including human, mouse, rat, pig, canine, chicken, and zebrafish

• Isoform detection:

  • Different antibodies may detect different TRIM63 isoforms

  • Compare results using antibodies targeting different epitopes (N-terminal vs. C-terminal)

  • Available antibodies target various regions including AA 254-352, AA 1-353, and N-terminal regions

• Experimental context differences:

  • In vitro vs. in vivo models may show different TRIM63 behavior

  • Stress conditions (e.g., atrophy-inducing vs. normal conditions) dramatically affect TRIM63 expression

  • Document all experimental conditions precisely when comparing results

• Technical variations:

  • Standardize protocols across experiments and models

  • Use positive and negative controls consistently

  • Consider blind analysis of results to reduce bias

• Data integration approaches:

  • Use multiple techniques to verify findings (e.g., WB, IF, qPCR)

  • Quantitative analysis with appropriate statistical methods

  • Meta-analysis of your results alongside published findings

• Mutant models interpretation:

  • Different TRIM63 mutations (e.g., A48V, I130M, Q247*) show varying degrees of functional impairment

  • Q247* mutation shows near complete loss of auto-ubiquitination

  • A48V and I130M show 60-70% reductions in auto-ubiquitination

How can TRIM63 antibodies be used to study its role in cardiac hypertrophy and cardiomyopathy?

TRIM63 has emerged as an important factor in cardiac pathophysiology, particularly in hypertrophic cardiomyopathy (HCM):

• Human studies applications:

  • Detection of TRIM63 protein levels in cardiac biopsy samples from HCM patients

  • Localization studies showing TRIM63 distribution in cardiomyocytes

  • Validation through IHC in human heart tissue at 1:50-1:500 dilution

• Model systems approaches:

  • Cardiac-restricted inducible transgenic mice expressing wild-type or mutant TRIM63 (A48V, I130M, Q247*) to study in vivo effects

  • Analysis of cardiac hypertrophy markers and signaling pathways in these models

  • Monitoring MTOR-S6K and calcineurin pathway activation in response to TRIM63 mutations

• Mechanistic studies:

  • Investigation of TRIM63's role in ubiquitinating cardiac proteins including:

    • Myosin heavy chain 6

    • Cardiac myosin binding protein C

    • Calcineurin (PPP3CB)

    • p-MTOR

  • Analysis of protein degradation pathways in cardiac tissue

• Clinical correlations:

  • Association of TRIM63 variants with disease severity

  • Longitudinal studies of TRIM63 expression in progressive cardiac disease

  • Potential therapeutic targeting of TRIM63 pathways

• Recommended methodological approaches:

  • Combination of antibody-based detection with genetic models

  • Multi-parameter analysis correlating TRIM63 function with cardiac phenotypes

  • Translational approaches connecting basic findings to clinical applications

What are the advanced protocols for studying TRIM63 interactions with other proteins?

Investigating TRIM63 protein interactions requires sophisticated approaches:

• Co-immunoprecipitation (Co-IP) with TRIM63 antibodies:

  • Use anti-TRIM63 antibodies to pull down TRIM63 and its binding partners

  • Alternatively, use Flag-tagged TRIM63 constructs and anti-Flag antibodies for cleaner results

  • Western blot for suspected interaction partners

  • Co-IP has successfully demonstrated TRIM63 auto-ubiquitination and interaction with target proteins

• Proximity labeling approaches:

  • BioID or APEX2-based proximity labeling fused to TRIM63

  • Allows identification of proteins in close proximity to TRIM63 in living cells

  • Especially useful for transient or weak interactions

• FRET/BRET analysis:

  • Fluorescence or Bioluminescence Resonance Energy Transfer

  • Requires fluorescent/luminescent protein fusions

  • Provides evidence of direct protein interactions in living cells

• Domain mapping:

  • Use of truncated TRIM63 constructs to identify interaction domains

  • Site-directed mutagenesis to pinpoint critical residues for interactions

  • Compare wild-type TRIM63 with disease-associated variants (A48V, I130M, Q247*)

• Mass spectrometry-based approaches:

  • Immunoprecipitation followed by mass spectrometry

  • SILAC labeling for quantitative comparison of interactomes

  • Crosslinking mass spectrometry for structural insights into complexes

• Visualization techniques:

  • Dual-color immunofluorescence using antibodies against TRIM63 and its partners

  • Acceptor photobleaching FRET microscopy

  • Super-resolution microscopy for detailed localization studies

How are cutting-edge technologies advancing our understanding of TRIM63 function?

Emerging technologies are transforming TRIM63 research:

• CRISPR/Cas9 applications:

  • Generation of precise TRIM63 knockout models

  • Introduction of patient-specific mutations to study variant effects

  • Base editing to correct pathogenic TRIM63 variants

  • These approaches provide more physiologically relevant models than traditional overexpression systems

• Single-cell techniques:

  • Single-cell RNA-seq to study TRIM63 expression heterogeneity

  • Single-cell proteomics for protein-level analysis

  • These methods reveal cell-to-cell variability in TRIM63 expression and function within tissues

• Advanced imaging:

  • Live-cell imaging of TRIM63 dynamics

  • FRET sensors to monitor TRIM63 activity in real-time

  • Super-resolution microscopy for precise localization

  • These techniques provide spatial and temporal information about TRIM63 function

• Proteomics advances:

  • Ubiquitinome analysis to identify TRIM63 substrates

  • Interaction proteomics to map TRIM63 protein complexes

  • Structural proteomics to understand TRIM63 conformation

  • These approaches expand our understanding of TRIM63's molecular functions

• Therapeutic targeting:

  • Small molecule modulators of TRIM63 activity

  • Gene therapy approaches to correct TRIM63 mutations

  • These interventions may lead to novel treatments for muscle and cardiac diseases

What are the best practices for reproducible TRIM63 antibody-based research?

Ensuring reproducibility in TRIM63 research requires adherence to rigorous standards:

• Comprehensive antibody validation:

  • Verify specificity using multiple approaches (knockout controls, peptide competition, etc.)

  • Test antibody performance in all planned applications

  • Document lot-to-lot variation

  • Consider using recombinant antibodies for increased consistency

• Detailed methods reporting:

  • Provide complete antibody information (catalog number, lot, clone, etc.)

  • For example: TRIM63 antibody (55456-1-AP) from Proteintech

  • Specify exact experimental conditions (dilutions, incubation times, buffers)

  • Share raw data and images when possible

• Appropriate controls:

  • Include positive and negative tissue controls

  • Use genetic models (knockout/knockdown) when available

  • Include isotype controls for immunostaining

  • For recombinant expression, compare tagged and untagged versions

• Quantitative analysis:

  • Use appropriate statistical methods

  • Perform power analyses to determine sample sizes

  • Consider blinded analysis of results

  • Report effect sizes along with statistical significance

• Data management:

  • Maintain comprehensive laboratory records

  • Use electronic lab notebooks with version control

  • Follow FAIR principles (Findable, Accessible, Interoperable, Reusable)

  • Consider pre-registration of experimental protocols